

Abington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	15.8	82.1	(43.7-140.4)	Male	11	9.9	111.1	(55.4-198.8)
Female	4	6.0	nc	(nc-nc)	Female	11	8.3	132.8	(66.2-237.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.2	187.3	(68.4-407.6)	Male	3	2.5	nc	(nc-nc)
Female	5	2.6	191.8	(61.8-447.6)	Female	2	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	9	8.7	103.5	(47.2-196.5)
Female	69	60.6	114.0	(88.7-144.2)	Female	7	7.9	88.8	(35.6-182.9)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	2.7	nc	(nc-nc)	Male	6	6.3	94.7	(34.6-206.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	23.7	75.8	(44.9-119.9)	Female	8	6.5	123.2	(53.0-242.7)
Female	38	23.0	165.6	(117.1-227.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	4.7	nc	(nc-nc)
Male	6	4.2	144.2	(52.7-313.9)	Female	1	5.0	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	51	62.6	81.5	(60.7-107.2)
Male	3	1.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.1	nc	(nc-nc)	Male	9	3.9	229.7	(104.8-436.1)
<u>Kidney and Renal Pelvis</u>					Female	1	2.4	nc	(nc-nc)
Male	7	7.4	94.1	(37.7-194.0)	<u>Testis</u>				
Female	5	4.6	108.1	(34.9-252.4)	Male	3	2.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.6	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	11	7.4	147.9	(73.7-264.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	5.3	149.7	(64.5-295.0)	Female	12	12.9	93.0	(48.0-162.5)
Female	3	4.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	217	217.0	100.0	(87.1-114.2)
Male	3	3.6	nc	(nc-nc)	Female	237	207.8	114.1	(100.0-129.5)
Female	0	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	41	30.0	136.8	(98.2-185.6)					
Female	35	28.7	121.9	(84.9-169.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	16.3	79.6	(42.4-136.2)	Male	17	11.6	146.0	(85.0-233.7)
Female	5	5.8	85.7	(27.6-200.0)	Female	16	9.9	161.0	(91.9-261.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.0	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	8	10.0	80.2	(34.5-158.0)
Female	92	72.3	127.2	(102.5-156.0)	Female	13	8.1	159.6	(84.9-272.9)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	3.5	nc	(nc-nc)	Male	4	7.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	25.7	93.3	(59.8-138.9)	Female	10	7.5	133.8	(64.0-246.1)
Female	17	22.4	76.0	(44.3-121.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	5.1	177.2	(80.9-336.4)
Male	1	4.7	nc	(nc-nc)	Female	5	4.8	104.8	(33.8-244.6)
Female	0	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	61	69.9	87.3	(66.8-112.2)
Male	1	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.3	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	1	2.3	nc	(nc-nc)
Male	6	8.8	68.2	(24.9-148.5)	<u>Testis</u>				
Female	5	5.0	99.7	(32.1-232.6)	Male	8	3.2	252.2	(108.6-497.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.0	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	11	9.9	111.6	(55.6-199.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	6.0	149.8	(68.4-284.4)	Female	15	15.2	98.6	(55.2-162.7)
Female	5	4.5	110.9	(35.7-258.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	212	241.5	87.8	(76.4-100.4)
Male	5	4.3	116.6	(37.6-272.2)	Female	236	229.0	103.1	(90.3-117.1)
Female	1	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	15	32.0	46.9	(26.2-77.3)					
Female	25	28.9	86.6	(56.0-127.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acushnet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	12.6	95.5	(49.3-166.9)	Male	5	7.5	66.7	(21.5-155.8)
Female	5	4.4	113.2	(36.5-264.2)	Female	2	5.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.4	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	6.6	90.5	(33.0-197.0)
Female	41	44.2	92.8	(66.6-125.9)	Female	2	5.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	1.9	nc	(nc-nc)	Male	1	4.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	18.6	118.2	(74.0-179.0)	Female	4	4.7	nc	(nc-nc)
Female	17	16.5	102.7	(59.8-164.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	3.7	134.5	(43.4-314.0)
Male	5	3.3	153.5	(49.5-358.2)	Female	2	3.6	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	50	49.1	101.7	(75.5-134.1)
Male	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.7	nc	(nc-nc)	Male	6	3.1	195.5	(71.4-425.5)
<u>Kidney and Renal Pelvis</u>					Female	1	1.7	nc	(nc-nc)
Male	9	5.7	157.1	(71.7-298.3)	<u>Testis</u>				
Female	4	3.4	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	2.0	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	5.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	4.0	nc	(nc-nc)	Female	7	9.5	73.5	(29.4-151.4)
Female	2	3.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	177	168.8	104.8	(90.0-121.5)
Male	4	2.8	nc	(nc-nc)	Female	125	151.1	82.7	(68.9-98.6)
Female	2	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	26	23.9	108.7	(71.0-159.2)					
Female	22	21.5	102.1	(64.0-154.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	12.5	136.1	(79.3-218.0)	Male	0	6.8	nc	(nc-nc)
Female	3	5.0	nc	(nc-nc)	Female	3	5.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.0	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	6.1	nc	(nc-nc)
Female	42	42.5	98.9	(71.3-133.7)	Female	5	6.2	80.3	(25.9-187.5)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	1.6	nc	(nc-nc)	Male	1	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	17.9	106.1	(63.9-165.7)	Female	7	4.7	149.2	(59.8-307.5)
Female	29	19.3	150.5	(100.7-216.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	3.6	166.6	(60.8-362.6)
Male	5	3.1	163.9	(52.8-382.5)	Female	5	4.2	118.1	(38.0-275.5)
Female	1	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	59	45.1	130.8	(99.6-168.7)
Male	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	1	2.1	nc	(nc-nc)
Male	8	5.2	154.8	(66.6-305.0)	<u>Testis</u>				
Female	5	3.5	141.2	(45.5-329.6)	Male	1	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	1.9	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	4.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	3.8	132.2	(42.6-308.5)	Female	10	9.1	110.0	(52.7-202.4)
Female	4	3.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	168	158.0	106.3	(90.8-123.6)
Male	3	2.5	nc	(nc-nc)	Female	172	156.1	110.2	(94.4-128.0)
Female	1	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	21	23.2	90.6	(56.1-138.6)					
Female	38	23.3	163.3	(115.5-224.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Agawam

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	34.3	96.2	(66.2-135.1)	Male	15	20.1	74.6	(41.7-123.0)
Female	12	14.4	83.3	(43.0-145.6)	Female	17	17.4	97.9	(57.0-156.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	6.2	nc	(nc-nc)	Male	4	5.4	nc	(nc-nc)
Female	7	5.4	128.6	(51.5-264.9)	Female	2	4.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	15	17.9	83.9	(46.9-138.5)
Female	140	130.7	107.1	(90.1-126.4)	Female	27	18.2	148.1	(97.6-215.5)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	5.4	nc	(nc-nc)	Male	10	12.7	78.8	(37.7-144.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	52	50.5	103.0	(76.9-135.1)	Female	19	14.3	133.3	(80.2-208.2)
Female	56	56.5	99.1	(74.9-128.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	10.1	89.3	(40.7-169.5)
Male	1	8.7	nc	(nc-nc)	Female	15	12.2	122.5	(68.5-202.1)
Female	4	2.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	112	127.3	88.0	(72.5-105.9)
Male	2	2.6	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.0	nc	(nc-nc)	Male	8	8.5	94.7	(40.8-186.6)
<u>Kidney and Renal Pelvis</u>					Female	4	6.1	nc	(nc-nc)
Male	17	15.1	112.5	(65.5-180.2)	<u>Testis</u>				
Female	13	10.4	125.3	(66.6-214.3)	Male	2	4.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	9	5.4	167.7	(76.5-318.4)	Male	4	4.5	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	13	14.2	91.6	(48.7-156.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	10.9	118.9	(63.2-203.3)	Female	27	27.7	97.5	(64.2-141.8)
Female	11	9.7	113.3	(56.5-202.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	408	449.3	90.8	(82.2-100.1)
Male	6	7.3	82.2	(30.0-179.0)	Female	484	467.0	103.6	(94.6-113.3)
Female	2	2.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	60	63.5	94.5	(72.1-121.7)					
Female	71	65.8	107.9	(84.2-136.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Alford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	5	2.0	245.2	(79.0-572.2)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	4	2.9	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	9	9.5	94.8	(43.3-180.0)
Male	0	0.2	nc	(nc-nc)	Female	9	6.6	135.5	(61.8-257.2)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.3	nc	(nc-nc)					
Female	1	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	15.5	64.3	(30.8-118.3)	Male	11	9.9	110.7	(55.2-198.2)
Female	5	6.2	80.2	(25.8-187.1)	Female	9	8.7	103.0	(47.0-195.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.3	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	9	8.7	103.7	(47.3-196.9)
Female	42	63.0	66.7	(48.0-90.1)	Female	13	8.2	159.4	(84.8-272.6)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	2.9	nc	(nc-nc)	Male	11	6.2	176.6	(88.1-316.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	23.4	81.4	(49.0-127.0)	Female	4	6.7	nc	(nc-nc)
Female	25	24.0	104.0	(67.3-153.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	4.6	nc	(nc-nc)
Male	6	4.1	146.9	(53.6-319.8)	Female	8	5.2	153.7	(66.2-302.8)
Female	1	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	57	60.9	93.6	(70.9-121.3)
Male	1	1.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.2	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	2.6	nc	(nc-nc)
Male	9	7.4	121.5	(55.5-230.7)	<u>Testis</u>				
Female	6	4.8	125.9	(46.0-274.1)	Male	5	2.6	191.4	(61.7-446.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.6	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	4	7.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	5.3	94.0	(30.3-219.4)	Female	16	13.2	121.3	(69.3-197.0)
Female	5	4.5	111.9	(36.0-261.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	201	213.8	94.0	(81.5-108.0)
Male	2	3.5	nc	(nc-nc)	Female	197	216.1	91.1	(78.9-104.8)
Female	2	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	28	29.5	95.0	(63.1-137.3)					
Female	31	29.3	105.8	(71.9-150.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amherst

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	17.3	34.7	(12.7-75.4)	Male	12	11.8	101.8	(52.5-177.8)
Female	6	7.2	83.1	(30.3-180.9)	Female	9	11.9	75.7	(34.5-143.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.3	nc	(nc-nc)	Male	5	2.8	181.1	(58.4-422.7)
Female	1	3.8	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	14	10.5	133.1	(72.7-223.4)
Female	92	73.0	126.0	(101.6-154.5)	Female	12	10.1	118.9	(61.4-207.7)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	4	3.6	nc	(nc-nc)	Male	5	7.1	70.4	(22.7-164.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	26.1	84.3	(52.8-127.7)	Female	8	8.5	94.1	(40.5-185.5)
Female	20	27.9	71.7	(43.8-110.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	5.2	96.8	(31.2-225.9)
Male	7	4.5	155.1	(62.1-319.6)	Female	0	6.0	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	77	67.2	114.5	(90.4-143.2)
Male	2	3.6	nc	(nc-nc)	<u>Stomach</u>				
Female	2	3.5	nc	(nc-nc)	Male	7	4.4	160.7	(64.4-331.0)
<u>Kidney and Renal Pelvis</u>					Female	0	3.0	nc	(nc-nc)
Male	6	8.1	74.5	(27.2-162.2)	<u>Testis</u>				
Female	4	5.6	nc	(nc-nc)	Male	4	6.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.8	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	7	12.2	57.2	(22.9-117.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	7.1	99.3	(39.8-204.5)	Female	19	15.6	122.1	(73.5-190.7)
Female	2	5.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	210	248.0	84.7	(73.6-96.9)
Male	0	4.0	nc	(nc-nc)	Female	223	261.9	85.2	(74.3-97.1)
Female	1	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	12	32.4	37.0	(19.1-64.7)					
Female	13	33.7	38.6	(20.5-66.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	32.6	85.8	(57.0-124.0)	Male	19	20.7	91.7	(55.2-143.2)
Female	10	12.7	79.0	(37.8-145.3)	Female	27	17.7	152.9	(100.8-222.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	6.8	117.5	(50.6-231.6)	Male	5	5.3	94.5	(30.5-220.6)
Female	5	5.6	89.6	(28.9-209.2)	Female	5	3.9	128.9	(41.5-300.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	16	18.1	88.2	(50.4-143.3)
Female	128	133.2	96.1	(80.2-114.2)	Female	18	16.7	108.0	(64.0-170.8)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	5.8	nc	(nc-nc)	Male	12	13.8	87.1	(44.9-152.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	43	49.6	86.7	(62.8-116.9)	Female	10	14.1	70.8	(33.9-130.2)
Female	40	49.0	81.6	(58.3-111.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	14	9.9	141.7	(77.4-237.7)
Male	6	8.8	68.0	(24.8-147.9)	Female	11	10.6	103.9	(51.8-186.0)
Female	2	2.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	184	132.7	138.7	(119.4-160.3)
Male	2	2.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	2.1	nc	(nc-nc)	Male	7	8.1	86.7	(34.7-178.6)
<u>Kidney and Renal Pelvis</u>					Female	3	5.2	nc	(nc-nc)
Male	12	15.9	75.5	(39.0-132.0)	<u>Testis</u>				
Female	11	9.9	111.2	(55.4-199.0)	Male	2	4.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	5.6	nc	(nc-nc)	Male	8	5.0	160.1	(68.9-315.5)
Female	1	1.5	nc	(nc-nc)	Female	23	15.8	145.4	(92.1-218.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	11.0	99.6	(49.6-178.2)	Female	24	28.2	85.0	(54.5-126.5)
Female	7	9.0	77.8	(31.2-160.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	463	454.6	101.8	(92.8-111.6)
Male	6	7.7	77.5	(28.3-168.7)	Female	397	446.8	88.9	(80.3-98.0)
Female	1	2.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	46	62.6	73.5	(53.8-98.0)					
Female	35	60.2	58.2	(40.5-80.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Aquinnah

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	1	0.5	nc	(nc-nc)	Male	13	3.9	331.4	(176.3-566.7)
Female	0	0.5	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Arlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	59	49.3	119.7	(91.1-154.4)	Male	35	29.0	120.6	(84.0-167.7)
Female	20	21.3	93.9	(57.3-145.1)	Female	25	26.6	93.9	(60.8-138.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	8.9	67.2	(24.5-146.3)	Male	10	7.7	130.7	(62.6-240.4)
Female	5	8.2	61.3	(19.8-143.0)	Female	11	6.5	169.7	(84.6-303.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.4	nc	(nc-nc)	Male	27	25.6	105.3	(69.4-153.3)
Female	204	196.5	103.8	(90.1-119.1)	Female	28	27.1	103.3	(68.6-149.3)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	8.4	nc	(nc-nc)	Male	12	17.7	67.8	(35.0-118.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	61	72.1	84.6	(64.7-108.7)	Female	19	21.3	89.3	(53.7-139.5)
Female	80	81.8	97.8	(77.5-121.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	14.4	83.5	(43.1-145.9)
Male	8	12.4	64.7	(27.9-127.5)	Female	17	17.9	95.2	(55.4-152.5)
Female	5	4.2	119.7	(38.6-279.3)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	169	184.7	91.5	(78.2-106.4)
Male	3	3.8	nc	(nc-nc)	<u>Stomach</u>				
Female	6	3.1	191.9	(70.1-417.8)	Male	10	12.1	82.9	(39.7-152.4)
<u>Kidney and Renal Pelvis</u>					Female	9	8.7	102.9	(47.0-195.3)
Male	18	21.7	83.0	(49.2-131.2)	<u>Testis</u>				
Female	11	15.6	70.5	(35.2-126.2)	Male	7	6.8	102.8	(41.2-211.8)
<u>Larynx</u>					<u>Thyroid</u>				
Male	13	7.7	169.9	(90.4-290.5)	Male	10	6.7	150.2	(71.9-276.3)
Female	5	2.4	208.8	(67.3-487.2)	Female	32	22.4	142.6	(97.5-201.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	18	15.6	115.3	(68.3-182.3)	Female	42	41.7	100.7	(72.6-136.2)
Female	13	14.3	91.2	(48.5-156.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	611	647.7	94.3	(87.0-102.1)
Male	9	10.4	86.9	(39.7-165.1)	Female	684	697.6	98.1	(90.8-105.7)
Female	3	4.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	69	92.4	74.7	(58.1-94.5)					
Female	72	99.8	72.1	(56.4-90.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashburnham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	4.8	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	16	19.1	83.6	(47.7-135.7)	Female	4	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	7.5	120.3	(54.9-228.4)	Female	1	2.0	nc	(nc-nc)
Female	6	6.0	100.7	(36.8-219.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	4	1.3	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	18	20.1	89.4	(53.0-141.3)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male				
Male	6	2.5	237.4	(86.7-516.7)	Male	0	1.2	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.9	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	1.7	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.2	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	7	9.3	74.9	(30.0-154.4)	Male	65	69.9	93.0	(71.7-118.5)
Female	5	7.8	64.0	(20.6-149.3)	Female	59	61.0	96.7	(73.6-124.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.5	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	4	0.9	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.6	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	7	10.0	69.7	(27.9-143.7)	Female	2	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	0.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	3.8	235.4	(107.4-446.9)	Female	0	1.0	nc	(nc-nc)
Female	8	3.4	238.6	(102.7-470.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.8	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	11	10.4	105.5	(52.6-188.8)
Male	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	1	0.3	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.9	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	34	35.9	94.6	(65.5-132.2)
Male	1	0.6	nc	(nc-nc)	Female	37	32.8	113.0	(79.5-155.7)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	4.8	nc	(nc-nc)					
Female	3	4.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	7	7.8	89.9	(36.0-185.2)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	3.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	8	8.1	98.5	(42.4-194.2)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.7	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	25	28.4	88.1	(57.0-130.1)
Male	0	0.5	nc	(nc-nc)	Female	17	24.8	68.7	(40.0-110.0)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	3.9	nc	(nc-nc)					
Female	1	3.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	13.4	156.5	(96.9-239.3)	Male	14	9.1	154.4	(84.3-259.0)
Female	5	4.7	105.9	(34.1-247.2)	Female	8	7.8	102.7	(44.2-202.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.0	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	6	2.4	250.1	(91.3-544.4)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	7.8	89.6	(35.9-184.7)
Female	68	55.9	121.7	(94.5-154.3)	Female	12	6.5	184.8	(95.4-322.8)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	2.7	nc	(nc-nc)	Male	6	5.8	102.9	(37.6-224.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	20.6	116.3	(74.5-173.1)	Female	7	5.8	120.4	(48.3-248.2)
Female	21	17.6	119.0	(73.7-182.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	4.1	122.7	(39.5-286.3)
Male	1	3.7	nc	(nc-nc)	Female	9	3.8	235.4	(107.4-446.9)
Female	0	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	49	55.2	88.7	(65.6-117.3)
Male	0	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	5	1.0	492.3	(158.7-1149.0)	Male	3	3.4	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	1	1.8	nc	(nc-nc)
Male	3	6.8	nc	(nc-nc)	<u>Testis</u>				
Female	1	4.0	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.3	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	10	7.7	130.7	(62.6-240.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	4.7	106.1	(34.2-247.5)	Female	13	11.8	109.8	(58.4-187.8)
Female	3	3.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	174	191.8	90.7	(77.8-105.3)
Male	3	3.3	nc	(nc-nc)	Female	208	180.1	115.5	(100.3-132.3)
Female	0	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	12	26.1	45.9	(23.7-80.2)					
Female	26	23.7	109.6	(71.6-160.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Athol

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	14.2	134.0	(80.7-209.3)	Male	7	8.1	86.8	(34.8-178.9)
Female	7	5.6	124.6	(49.9-256.8)	Female	5	6.6	75.8	(24.4-176.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.5	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	8	7.2	110.6	(47.6-217.9)
Female	42	49.4	85.1	(61.3-115.0)	Female	6	7.1	84.8	(31.0-184.6)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	25	20.5	121.8	(78.8-179.8)	Female	7	5.4	129.3	(51.8-266.3)
Female	22	21.9	100.3	(62.8-151.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	4.1	nc	(nc-nc)
Male	2	3.5	nc	(nc-nc)	Female	8	4.8	167.6	(72.2-330.2)
Female	2	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	53	50.6	104.7	(78.4-136.9)
Male	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.8	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	2.4	nc	(nc-nc)
Male	4	6.0	nc	(nc-nc)	<u>Testis</u>				
Female	1	4.0	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.1	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	5.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	4.5	133.3	(48.7-290.1)	Female	9	10.4	86.8	(39.6-164.8)
Female	7	3.8	184.3	(73.9-379.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	186	181.2	102.6	(88.4-118.5)
Male	4	2.9	nc	(nc-nc)	Female	169	179.2	94.3	(80.6-109.7)
Female	2	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	28	25.8	108.3	(72.0-156.6)					
Female	31	25.6	121.0	(82.2-171.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Attleboro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	40.5	106.3	(76.9-143.2)	Male	23	25.6	89.8	(56.9-134.8)
Female	17	16.7	101.7	(59.2-162.9)	Female	27	22.7	118.8	(78.3-172.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	8.4	118.8	(56.9-218.5)	Male	3	6.4	nc	(nc-nc)
Female	10	7.2	139.7	(66.9-256.9)	Female	5	5.1	98.7	(31.8-230.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.2	nc	(nc-nc)	Male	21	22.5	93.5	(57.9-143.0)
Female	165	162.0	101.8	(86.9-118.6)	Female	20	21.8	91.7	(56.0-141.6)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	7.5	nc	(nc-nc)	Male	18	15.9	113.3	(67.1-179.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	63	60.5	104.2	(80.1-133.3)	Female	21	17.5	120.2	(74.4-183.8)
Female	60	64.5	93.0	(71.0-119.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	12.0	83.1	(39.8-152.9)
Male	17	10.5	161.3	(93.9-258.2)	Female	13	14.0	92.9	(49.4-158.9)
Female	1	3.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	126	157.3	80.1	(66.7-95.4)
Male	6	3.9	152.9	(55.8-332.8)	<u>Stomach</u>				
Female	1	3.1	nc	(nc-nc)	Male	15	10.0	149.7	(83.7-246.9)
<u>Kidney and Renal Pelvis</u>					Female	5	6.9	72.3	(23.3-168.8)
Male	22	19.0	115.8	(72.6-175.4)	<u>Testis</u>				
Female	10	12.6	79.6	(38.1-146.4)	Male	5	7.1	70.0	(22.5-163.3)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	6.6	nc	(nc-nc)	Male	5	6.4	78.5	(25.3-183.2)
Female	2	1.9	nc	(nc-nc)	Female	21	20.3	103.3	(63.9-157.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	13.8	94.0	(50.0-160.7)	Female	30	34.2	87.8	(59.2-125.4)
Female	10	11.9	84.3	(40.4-155.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	537	553.7	97.0	(88.9-105.5)
Male	10	9.0	110.8	(53.1-203.9)	Female	544	567.5	95.9	(88.0-104.3)
Female	5	3.4	146.3	(47.2-341.5)					
<u>Lung and Bronchus</u>									
Male	86	76.7	112.1	(89.7-138.5)					
Female	81	78.3	103.5	(82.2-128.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Auburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	21.9	105.0	(66.5-157.5)	Male	5	12.4	40.4	(13.0-94.3)
Female	9	8.3	108.5	(49.5-206.0)	Female	4	10.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.8	nc	(nc-nc)	Male	6	3.4	177.8	(64.9-387.1)
Female	7	3.1	222.3	(89.0-458.0)	Female	1	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	7	11.1	63.3	(25.4-130.4)
Female	51	76.4	66.8	(49.7-87.8)	Female	8	10.5	76.2	(32.8-150.1)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	3.1	nc	(nc-nc)	Male	8	7.8	103.1	(44.4-203.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	34	31.9	106.7	(73.9-149.1)	Female	7	8.3	84.3	(33.8-173.8)
Female	30	31.8	94.3	(63.6-134.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	6.4	78.2	(25.2-182.6)
Male	9	5.5	164.5	(75.1-312.2)	Female	7	6.9	100.7	(40.4-207.5)
Female	3	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	68	81.7	83.2	(64.6-105.5)
Male	2	1.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.1	nc	(nc-nc)	Male	2	5.3	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	4	3.4	nc	(nc-nc)
Male	3	9.4	nc	(nc-nc)	<u>Testis</u>				
Female	9	6.1	147.9	(67.5-280.8)	Male	6	2.3	257.3	(94.0-560.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	3.4	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	6	8.2	73.1	(26.7-159.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	6.8	nc	(nc-nc)	Female	24	16.4	146.2	(93.7-217.6)
Female	4	5.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	249	284.0	87.7	(77.1-99.3)
Male	8	4.5	177.1	(76.3-349.1)	Female	249	270.5	92.1	(81.0-104.2)
Female	0	1.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	31	40.9	75.9	(51.5-107.7)					
Female	51	39.0	130.6	(97.3-171.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Avon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.7	104.9	(38.3-228.3)	Male	5	3.3	153.4	(49.4-358.0)
Female	1	2.1	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	8	20.3	39.5	(17.0-77.8)	Female	2	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	0.8	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	8.3	108.1	(49.3-205.3)	Female	0	2.2	nc	(nc-nc)
Female	14	7.9	178.2	(97.3-299.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	1.4	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	16	22.0	72.7	(41.5-118.0)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male				
Male	3	2.5	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	1.8	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.2	nc	(nc-nc)	Female	6	4.4	135.4	(49.5-294.8)
Female	2	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	12	10.8	110.6	(57.1-193.3)	Male	74	75.2	98.4	(77.3-123.6)
Female	15	10.5	142.8	(79.9-235.6)	Female	72	70.6	102.0	(79.8-128.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ayer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	6.3	79.0	(25.5-184.3)	Male	2	4.1	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.4	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	22	25.7	85.6	(53.6-129.6)	Female	4	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	9.5	105.7	(50.6-194.4)	Female	6	2.8	215.9	(78.8-470.0)
Female	11	10.5	105.2	(52.5-188.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	1.9	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	19	24.6	77.1	(46.4-120.5)
Male	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	1.1	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.0	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	6	3.3	182.3	(66.6-396.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.2	nc	(nc-nc)	Female	2	5.4	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	76	87.3	87.0	(68.6-108.9)
Male	1	1.4	nc	(nc-nc)	Female	87	91.0	95.6	(76.6-118.0)
Female	2	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	15	12.1	124.3	(69.5-205.0)					
Female	13	12.5	103.7	(55.1-177.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barnstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	83	73.9	112.4	(89.5-139.3)	Male	52	39.6	131.3	(98.0-172.1)
Female	19	25.9	73.2	(44.1-114.4)	Female	55	30.3	181.7	(136.8-236.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	11.8	110.2	(58.6-188.5)	Male	8	11.1	72.0	(31.0-141.8)
Female	13	9.5	136.2	(72.4-232.9)	Female	9	7.9	113.9	(52.0-216.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	2.0	nc	(nc-nc)	Male	34	35.8	95.0	(65.8-132.7)
Female	244	232.8	104.8	(92.1-118.8)	Female	24	32.4	74.0	(47.4-110.2)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	9	9.2	97.6	(44.5-185.2)	Male	29	24.0	120.7	(80.8-173.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	101	105.4	95.8	(78.1-116.5)	Female	24	25.4	94.7	(60.6-140.9)
Female	103	98.0	105.1	(85.8-127.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	29	21.2	137.0	(91.7-196.8)
Male	11	17.8	61.8	(30.8-110.6)	Female	41	21.6	189.4	(135.9-257.0)
Female	3	5.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	369	263.8	139.9	(126.0-154.9)
Male	6	4.6	130.4	(47.6-283.9)	<u>Stomach</u>				
Female	3	3.5	nc	(nc-nc)	Male	16	17.8	89.6	(51.2-145.6)
<u>Kidney and Renal Pelvis</u>					Female	12	10.3	116.0	(59.9-202.7)
Male	39	30.0	130.0	(92.4-177.7)	<u>Testis</u>				
Female	23	18.9	121.9	(77.2-182.9)	Male	6	6.9	87.2	(31.8-189.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	10.9	nc	(nc-nc)	Male	4	8.0	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	Female	13	24.3	53.5	(28.4-91.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	28	22.1	126.4	(84.0-182.8)	Female	44	50.2	87.7	(63.7-117.7)
Female	25	16.8	148.7	(96.2-219.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1036	926.1	111.9	(105.2-118.9)
Male	10	14.4	69.7	(33.4-128.1)	Female	883	831.5	106.2	(99.3-113.4)
Female	8	5.1	155.9	(67.1-307.1)					
<u>Lung and Bronchus</u>									
Male	115	136.0	84.6	(69.8-101.5)					
Female	122	123.3	99.0	(82.2-118.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barre

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	5.4	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	17	19.4	87.8	(51.1-140.6)	Female	3	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	8.1	74.1	(27.1-161.3)	Female	2	2.1	nc	(nc-nc)
Female	2	7.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	2	1.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	12	20.3	59.2	(30.5-103.4)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male				
Male	1	2.5	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	1.8	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.2	nc	(nc-nc)	Female	1	4.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	15	10.1	147.9	(82.7-244.0)	Male	56	72.7	77.0	(58.2-100.0)
Female	11	9.2	119.6	(59.6-214.0)	Female	52	66.8	77.8	(58.1-102.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Becket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.4	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	7	7.0	99.3	(39.8-204.6)	Female	2	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	3.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	0.6	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.2	nc	(nc-nc)	Female	3	9.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male				
Male	1	1.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	2	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	0.7	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.5	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	9	4.5	199.6	(91.1-379.0)	Female	28	31.9	87.7	(58.2-126.7)
Female	6	3.2	187.4	(68.4-407.8)	Female	27	23.1	117.0	(77.1-170.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	20.5	78.1	(44.6-126.8)	Male	16	11.1	144.1	(82.3-234.0)
Female	6	5.9	101.1	(36.9-220.0)	Female	8	7.3	109.5	(47.1-215.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.3	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	11	10.0	110.0	(54.8-196.8)
Female	69	56.1	122.9	(95.7-155.6)	Female	3	7.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	2.3	nc	(nc-nc)	Male	4	6.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	26	29.4	88.5	(57.8-129.6)	Female	9	6.0	149.1	(68.0-283.1)
Female	16	22.9	70.0	(40.0-113.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	5.9	nc	(nc-nc)
Male	3	5.0	nc	(nc-nc)	Female	7	5.0	140.7	(56.4-289.9)
Female	1	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	63	73.7	85.5	(65.7-109.4)
Male	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.8	nc	(nc-nc)	Male	4	5.0	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	2.4	nc	(nc-nc)
Male	9	8.5	106.4	(48.5-201.9)	<u>Testis</u>				
Female	2	4.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	3.0	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	9	6.1	148.1	(67.6-281.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	6.2	97.3	(35.5-211.8)	Female	9	12.1	74.5	(34.0-141.5)
Female	2	4.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	223	258.2	86.4	(75.4-98.5)
Male	3	4.0	nc	(nc-nc)	Female	184	196.0	93.9	(80.8-108.4)
Female	3	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	25	37.7	66.3	(42.9-97.8)					
Female	23	27.7	83.0	(52.6-124.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belchertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	11.2	80.6	(36.8-153.0)	Male	9	7.6	118.8	(54.2-225.5)
Female	4	3.9	nc	(nc-nc)	Female	12	6.6	182.6	(94.2-319.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.6	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	6	2.0	297.2	(108.5-646.8)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	6.6	nc	(nc-nc)
Female	46	46.1	99.7	(73.0-133.0)	Female	4	5.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	2.3	nc	(nc-nc)	Male	5	4.9	103.1	(33.2-240.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	17.2	110.7	(66.6-172.8)	Female	7	4.8	145.3	(58.2-299.3)
Female	9	14.9	60.5	(27.6-114.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	3.4	nc	(nc-nc)
Male	6	3.0	198.5	(72.5-432.1)	Female	6	3.2	187.5	(68.5-408.2)
Female	1	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	40	43.9	91.1	(65.1-124.0)
Male	3	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.9	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	1	1.5	nc	(nc-nc)
Male	3	5.6	nc	(nc-nc)	<u>Testis</u>				
Female	7	3.3	213.9	(85.7-440.7)	Male	4	2.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.9	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	7	6.5	107.4	(43.0-221.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.0	nc	(nc-nc)	Female	10	9.6	104.5	(50.0-192.1)
Female	2	3.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	142	157.5	90.2	(76.0-106.3)
Male	1	2.7	nc	(nc-nc)	Female	149	149.4	99.7	(84.3-117.1)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	17	21.2	80.1	(46.6-128.2)					
Female	17	19.2	88.4	(51.4-141.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bellingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	13.4	89.4	(46.1-156.2)	Male	7	9.1	77.0	(30.9-158.7)
Female	6	4.8	125.0	(45.7-272.1)	Female	10	7.7	130.5	(62.5-240.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.1	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	5	2.4	208.5	(67.2-486.7)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	7.8	89.3	(35.8-184.1)
Female	49	55.2	88.8	(65.7-117.5)	Female	9	6.5	137.6	(62.8-261.2)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	2.7	nc	(nc-nc)	Male	7	5.9	118.5	(47.5-244.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	21	20.7	101.7	(62.9-155.5)	Female	7	5.8	121.1	(48.5-249.5)
Female	12	17.8	67.4	(34.8-117.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	4.1	nc	(nc-nc)
Male	3	3.7	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	55	57.0	96.5	(72.7-125.6)
Male	2	1.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.0	nc	(nc-nc)	Male	8	3.3	239.7	(103.2-472.4)
<u>Kidney and Renal Pelvis</u>					Female	3	1.8	nc	(nc-nc)
Male	7	6.9	101.6	(40.7-209.3)	<u>Testis</u>				
Female	7	4.0	174.7	(70.0-360.1)	Male	3	2.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	2.4	211.0	(68.0-492.4)	Male	3	2.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	4	7.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	4.7	147.4	(59.0-303.7)	Female	14	11.9	118.0	(64.5-198.0)
Female	5	3.5	141.4	(45.6-330.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	210	194.2	108.1	(94.0-123.8)
Male	2	3.3	nc	(nc-nc)	Female	202	179.9	112.3	(97.3-128.9)
Female	0	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	44	26.4	166.8	(121.2-223.9)					
Female	42	24.2	173.8	(125.2-234.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belmont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	30.3	72.6	(45.5-110.0)	Male	23	17.3	132.9	(84.2-199.4)
Female	4	11.7	nc	(nc-nc)	Female	24	14.7	163.4	(104.6-243.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.3	94.2	(30.4-219.8)	Male	1	4.7	nc	(nc-nc)
Female	4	4.6	nc	(nc-nc)	Female	1	3.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	16	15.4	103.6	(59.2-168.2)
Female	115	110.6	104.0	(85.8-124.8)	Female	20	15.0	133.3	(81.4-205.8)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	4.7	nc	(nc-nc)	Male	8	10.8	74.4	(32.0-146.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	38	44.1	86.2	(61.0-118.4)	Female	15	11.9	125.6	(70.3-207.2)
Female	45	45.5	98.9	(72.1-132.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	8.8	79.4	(31.8-163.6)
Male	4	7.5	nc	(nc-nc)	Female	18	9.9	182.2	(107.9-287.9)
Female	3	2.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	99	112.0	88.4	(71.8-107.6)
Male	1	2.1	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.7	nc	(nc-nc)	Male	4	7.4	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	3	4.9	nc	(nc-nc)
Male	9	13.0	69.1	(31.5-131.3)	<u>Testis</u>				
Female	6	8.7	69.2	(25.3-150.7)	Male	6	3.4	176.2	(64.3-383.6)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	4.7	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	16	12.4	129.4	(73.9-210.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	9.5	84.3	(36.3-166.2)	Female	20	23.5	85.3	(52.1-131.7)
Female	12	7.9	151.3	(78.1-264.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	316	392.3	80.6	(71.9-89.9)
Male	3	6.2	nc	(nc-nc)	Female	382	388.5	98.3	(88.7-108.7)
Female	1	2.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	29	56.1	51.7	(34.6-74.2)					
Female	36	54.7	65.8	(46.0-91.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berkley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.0	125.0	(40.3-291.8)	Male	3	3.1	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	3	0.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	16	17.5	91.6	(52.3-148.8)	Female	3	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	1.0	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	6.4	109.5	(43.9-225.7)	Female	2	1.8	nc	(nc-nc)
Female	4	5.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	3	1.2	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	20	17.4	114.6	(70.0-177.1)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male				
Male	2	2.3	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	1.6	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	7	2.8	249.5	(100.0-514.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.1	nc	(nc-nc)	Female	5	3.6	140.4	(45.3-327.7)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	7	7.9	88.2	(35.4-181.8)	Male	62	61.2	101.2	(77.6-129.8)
Female	7	6.6	105.4	(42.2-217.2)	Female	65	55.1	117.9	(91.0-150.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berlin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.7	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.5	nc	(nc-nc)
Female	16	10.3	155.0	(88.5-251.7)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	4.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	7	3.5	198.4	(79.5-408.8)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	11	11.6	95.1	(47.4-170.2)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney and Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.4	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Male	37	38.8	95.4	(67.1-131.5)
Female	0	0.1	nc	(nc-nc)	Female	40	34.0	117.6	(84.0-160.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	3	5.3	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	4	4.7	nc	(nc-nc)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bernardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	2.9	205.9	(75.2-448.3)	Male	2	1.7	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	12	10.1	119.1	(61.4-208.0)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	4.3	139.5	(50.9-303.7)	Female	2	1.1	nc	(nc-nc)
Female	2	3.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.9	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	11	11.4	96.5	(48.1-172.7)
Male	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	1	0.4	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.8	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	0.9	nc	(nc-nc)	Female	10	2.2	461.4	(220.9-848.6)
Female	0	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	38	38.9	97.8	(69.2-134.2)
Male	0	0.6	nc	(nc-nc)	Female	41	34.4	119.2	(85.5-161.7)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	5.5	nc	(nc-nc)					
Female	3	4.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Beverly

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	50	44.8	111.5	(82.8-147.0)	Male	25	26.6	94.1	(60.9-138.9)
Female	21	18.8	111.7	(69.1-170.8)	Female	26	23.2	112.0	(73.1-164.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	8.4	167.6	(91.6-281.2)	Male	4	7.0	nc	(nc-nc)
Female	10	7.3	136.8	(65.5-251.6)	Female	3	5.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.3	nc	(nc-nc)	Male	15	23.6	63.7	(35.6-105.0)
Female	152	171.0	88.9	(75.3-104.2)	Female	29	23.9	121.4	(81.3-174.3)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	7.3	nc	(nc-nc)	Male	18	16.5	109.2	(64.7-172.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	49	65.9	74.3	(55.0-98.3)	Female	29	18.7	155.3	(104.0-223.1)
Female	64	73.4	87.1	(67.1-111.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	13.1	68.5	(31.3-130.0)
Male	13	11.3	114.8	(61.1-196.3)	Female	12	15.9	75.4	(38.9-131.7)
Female	4	3.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	154	167.6	91.9	(77.9-107.6)
Male	3	3.6	nc	(nc-nc)	<u>Stomach</u>				
Female	1	3.0	nc	(nc-nc)	Male	5	11.0	45.4	(14.6-105.9)
<u>Kidney and Renal Pelvis</u>					Female	3	8.0	nc	(nc-nc)
Male	22	19.9	110.8	(69.4-167.7)	<u>Testis</u>				
Female	25	13.6	184.0	(119.0-271.6)	Male	9	6.1	147.3	(67.2-279.6)
<u>Larynx</u>					<u>Thyroid</u>				
Male	10	7.0	142.9	(68.4-262.9)	Male	6	6.1	98.6	(36.0-214.6)
Female	4	2.1	nc	(nc-nc)	Female	22	19.5	112.9	(70.7-170.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	14.5	75.9	(37.8-135.8)	Female	42	35.9	117.0	(84.3-158.2)
Female	11	12.9	85.4	(42.6-152.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	556	591.1	94.1	(86.4-102.2)
Male	6	9.6	62.6	(22.8-136.2)	Female	633	612.4	103.4	(95.5-111.7)
Female	2	3.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	89	83.6	106.4	(85.5-131.0)					
Female	106	86.0	123.2	(100.9-149.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Billerica

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	31.5	98.3	(66.8-139.5)	Male	23	22.5	102.3	(64.8-153.5)
Female	14	11.4	122.3	(66.8-205.2)	Female	11	18.6	59.1	(29.4-105.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	7.7	78.0	(28.5-169.7)	Male	7	5.3	131.7	(52.8-271.5)
Female	7	5.8	120.2	(48.1-247.6)	Female	3	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.0	nc	(nc-nc)	Male	18	19.2	93.6	(55.4-147.9)
Female	132	134.3	98.3	(82.2-116.6)	Female	12	15.8	76.2	(39.3-133.1)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	5	6.5	77.2	(24.9-180.1)	Male	21	14.9	140.5	(86.9-214.8)
<u>Colon / Rectum</u>					Female	13	6.2	210.7	(112.1-360.4)
Male	42	49.5	84.9	(61.2-114.8)	<u>Ovary</u>				
Female	34	42.9	79.2	(54.8-110.7)	Female	15	14.1	106.5	(59.6-175.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	9.1	121.2	(60.4-216.8)	Male	7	9.8	71.1	(28.5-146.5)
Female	2	2.2	nc	(nc-nc)	Female	7	9.3	75.4	(30.2-155.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	3.7	136.4	(43.9-318.3)	Male	148	139.2	106.3	(89.9-124.9)
Female	3	2.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	4	7.9	nc	(nc-nc)
Male	25	17.0	147.2	(95.2-217.3)	Female	0	4.4	nc	(nc-nc)
Female	9	9.6	93.6	(42.7-177.7)	<u>Testis</u>				
<u>Larynx</u>					Male	5	6.8	73.2	(23.6-170.8)
Male	4	5.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	1.5	nc	(nc-nc)	Male	6	6.2	97.5	(35.6-212.2)
<u>Leukemia</u>					Female	18	18.1	99.3	(58.8-156.9)
Male	9	11.6	77.5	(35.4-147.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	16	8.5	188.2	(107.5-305.6)	Female	28	29.2	95.8	(63.7-138.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	8.1	nc	(nc-nc)	Male	506	472.0	107.2	(98.1-117.0)
Female	7	2.4	293.3	(117.5-604.4)	Female	453	435.1	104.1	(94.7-114.2)
<u>Lung and Bronchus</u>									
Male	86	62.6	137.4	(109.9-169.7)					
Female	73	57.2	127.7	(100.1-160.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blackstone

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	7.5	146.4	(73.0-262.0)	Male	4	5.0	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.7	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	4.4	nc	(nc-nc)
Female	25	30.5	81.9	(53.0-120.9)	Female	8	3.8	209.7	(90.3-413.3)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	11.4	104.9	(54.1-183.2)	Female	3	3.2	nc	(nc-nc)
Female	13	10.6	122.1	(64.9-208.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.3	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
Female	3	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	26	29.7	87.6	(57.2-128.3)
Male	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	2	1.1	nc	(nc-nc)
Male	8	3.7	215.9	(92.9-425.4)	<u>Testis</u>				
Female	5	2.3	220.9	(71.2-515.5)	Male	0	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	5	4.1	121.2	(39.1-282.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.7	nc	(nc-nc)	Female	8	6.4	124.8	(53.7-245.8)
Female	1	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	102	105.5	96.6	(78.8-117.3)
Male	0	1.8	nc	(nc-nc)	Female	116	102.3	113.4	(93.7-136.0)
Female	1	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	24	14.3	167.8	(107.5-249.7)					
Female	19	13.8	137.4	(82.7-214.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blandford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	6	4.7	127.8	(46.7-278.1)	Female	1	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	2.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	7	5.4	129.1	(51.7-266.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male				
Male	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.3	nc	(nc-nc)	Male	14	18.3	76.6	(41.8-128.5)
Female	0	0.1	nc	(nc-nc)	Female	21	14.7	142.4	(88.1-217.7)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	2	2.5	nc	(nc-nc)					
Female	4	1.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bolton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.2	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	16	14.4	111.0	(63.4-180.3)	Female	0	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	5.2	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	5	3.9	129.2	(41.6-301.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	2	1.0	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	11	14.7	74.8	(37.3-133.9)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male				
Male	2	1.9	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.6	nc	(nc-nc)	Male	3	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	1.2	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.9	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	5	6.4	78.6	(25.3-183.3)	Male	48	49.6	96.7	(71.3-128.2)
Female	4	5.2	nc	(nc-nc)	Female	43	43.6	98.7	(71.4-132.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	352	450.9	78.1	(70.1-86.7)	Male	254	293.4	86.6	(76.2-97.9)
Female	157	187.8	83.6	(71.0-97.7)	Female	234	279.3	83.8	(73.4-95.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	66	98.0	67.3	(52.1-85.7)	Male	80	71.7	111.5	(88.4-138.8)
Female	68	86.4	78.7	(61.1-99.7)	Female	79	56.8	139.2	(110.2-173.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	18	12.9	139.8	(82.8-220.9)	Male	272	256.9	105.9	(93.7-119.3)
Female	1801	1852.9	97.2	(92.8-101.8)	Female	226	250.9	90.1	(78.7-102.6)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	129	92.1	140.0	(116.9-166.4)	Male	224	174.8	128.1	(111.9-146.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	716	673.3	106.3	(98.7-114.4)	Female	196	202.1	97.0	(83.9-111.6)
Female	778	717.8	108.4	(100.9-116.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	149	133.3	111.8	(94.6-131.3)
Male	111	116.1	95.6	(78.7-115.1)	Female	156	155.9	100.0	(85.0-117.0)
Female	39	36.6	106.5	(75.7-145.6)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1944	1722.1	112.9	(107.9-118.0)
Male	49	54.9	89.2	(66.0-118.0)	<u>Stomach</u>				
Female	52	47.4	109.8	(82.0-144.0)	Male	141	112.5	125.4	(105.5-147.9)
<u>Kidney and Renal Pelvis</u>					Female	123	76.5	160.8	(133.6-191.8)
Male	222	210.1	105.7	(92.2-120.5)	<u>Testis</u>				
Female	160	143.6	111.4	(94.8-130.1)	Male	75	105.7	70.9	(55.8-88.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	76	72.3	105.1	(82.8-131.5)	Male	91	76.5	118.9	(95.7-146.0)
Female	24	22.1	108.8	(69.7-161.9)	Female	322	263.9	122.0	(109.0-136.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	158	160.5	98.4	(83.7-115.0)	Female	380	391.9	97.0	(87.5-107.2)
Female	138	137.3	100.5	(84.4-118.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	6706	6205.8	108.1	(105.5-110.7)
Male	192	99.8	192.4	(166.1-221.6)	Female	6684	6531.1	102.3	(99.9-104.8)
Female	53	38.6	137.3	(102.9-179.6)					
<u>Lung and Bronchus</u>									
Male	978	848.0	115.3	(108.2-122.8)					
Female	910	890.1	102.2	(95.7-109.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bourne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	25.4	94.3	(60.4-140.4)	Male	21	14.1	148.6	(91.9-227.1)
Female	14	9.2	152.4	(83.2-255.7)	Female	10	11.0	90.5	(43.3-166.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.3	nc	(nc-nc)	Male	8	3.9	206.9	(89.1-407.8)
Female	6	3.5	171.4	(62.6-373.0)	Female	3	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	12	12.7	94.6	(48.8-165.3)
Female	84	83.1	101.1	(80.6-125.1)	Female	12	11.6	103.9	(53.6-181.4)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	3.4	nc	(nc-nc)	Male	10	8.6	115.9	(55.5-213.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	40	36.6	109.2	(78.0-148.7)	Female	8	9.1	88.1	(37.9-173.6)
Female	39	34.8	112.1	(79.7-153.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	7.3	nc	(nc-nc)
Male	8	6.3	127.9	(55.1-252.1)	Female	6	7.7	78.4	(28.6-170.6)
Female	2	1.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	108	93.8	115.2	(94.5-139.1)
Male	3	1.9	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.4	nc	(nc-nc)	Male	4	6.2	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	4	3.7	nc	(nc-nc)
Male	5	10.7	46.8	(15.1-109.3)	<u>Testis</u>				
Female	5	6.7	74.4	(24.0-173.7)	Male	2	3.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	3.8	156.0	(57.0-339.6)	Male	3	3.0	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	5	9.1	55.1	(17.8-128.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	7.9	151.7	(78.3-265.0)	Female	24	18.0	133.0	(85.2-197.9)
Female	7	6.1	115.2	(46.1-237.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	366	327.1	111.9	(100.7-124.0)
Male	6	5.1	117.3	(42.8-255.3)	Female	340	297.2	114.4	(102.6-127.2)
Female	5	1.8	272.1	(87.7-635.1)					
<u>Lung and Bronchus</u>									
Male	59	47.5	124.3	(94.6-160.3)					
Female	65	43.5	149.3	(115.2-190.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.0	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	12	14.4	83.2	(42.9-145.4)	Female	3	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	0.8	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	5.0	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Female	7	3.5	199.7	(80.0-411.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	12	13.4	89.3	(46.1-156.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney and Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.8	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	0.9	nc	(nc-nc)	Male	2	6.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	5	4.9	102.7	(33.1-239.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	7.8	nc	(nc-nc)	Male	11	5.2	212.8	(106.1-380.8)
Female	3	2.4	nc	(nc-nc)	Female	6	3.9	152.4	(55.6-331.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	4.5	156.0	(62.5-321.5)
Female	45	29.9	150.4	(109.7-201.3)	Female	3	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	5	3.6	140.8	(45.4-328.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	12.1	140.9	(82.0-225.6)	Female	2	3.1	nc	(nc-nc)
Female	9	8.9	100.6	(45.9-190.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	2	2.2	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	34	33.4	101.9	(70.5-142.3)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male				
Male	3	4.0	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.4	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	2.7	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.0	nc	(nc-nc)	Female	6	6.3	94.7	(34.6-206.2)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	6	15.3	39.3	(14.3-85.5)	Male	103	112.5	91.6	(74.7-111.1)
Female	14	12.0	116.7	(63.7-195.8)	Female	112	93.4	120.0	(98.8-144.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.4	113.8	(36.7-265.7)	Male	4	2.8	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	22	16.6	132.4	(82.9-200.4)	Female	2	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	6.7	104.5	(41.9-215.4)	Female	2	1.7	nc	(nc-nc)
Female	4	5.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.3	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	22	18.4	119.3	(74.7-180.6)
Male	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	0.6	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<u>Testis</u>				
Female	0	1.2	nc	(nc-nc)	Male	3	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	1.5	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	63	62.2	101.3	(77.9-129.6)
Male	0	1.1	nc	(nc-nc)	Female	49	54.2	90.4	(66.9-119.6)
Female	1	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	8.5	81.9	(32.8-168.9)					
Female	4	7.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	49	44.4	110.4	(81.7-146.0)	Male	29	24.9	116.6	(78.1-167.5)
Female	11	17.7	62.0	(30.9-110.9)	Female	24	21.0	114.5	(73.3-170.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	7.6	104.6	(45.0-206.1)	Male	1	6.8	nc	(nc-nc)
Female	7	6.6	105.4	(42.2-217.1)	Female	3	5.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.2	nc	(nc-nc)	Male	21	22.3	94.4	(58.4-144.2)
Female	158	160.3	98.6	(83.8-115.2)	Female	19	22.2	85.5	(51.5-133.5)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	9	6.4	140.1	(63.9-265.9)	Male	16	15.5	103.2	(59.0-167.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	78	64.3	121.4	(95.9-151.5)	Female	17	17.4	97.5	(56.7-156.0)
Female	84	67.7	124.2	(99.0-153.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	15	12.9	116.1	(64.9-191.5)
Male	11	11.1	99.5	(49.6-178.0)	Female	9	14.9	60.6	(27.6-115.0)
Female	4	3.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	149	166.3	89.6	(75.8-105.2)
Male	2	3.1	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.4	nc	(nc-nc)	Male	12	10.8	111.4	(57.5-194.6)
<u>Kidney and Renal Pelvis</u>					Female	7	7.2	97.2	(38.9-200.3)
Male	18	19.0	94.6	(56.0-149.5)	<u>Testis</u>				
Female	11	12.9	85.4	(42.6-152.9)	Male	2	4.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	6.8	nc	(nc-nc)	Male	5	5.4	93.4	(30.1-217.9)
Female	1	2.0	nc	(nc-nc)	Female	14	17.0	82.6	(45.1-138.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	18	13.8	130.7	(77.4-206.5)	Female	28	34.6	80.9	(53.8-117.0)
Female	15	11.7	128.2	(71.7-211.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	564	575.0	98.1	(90.2-106.5)
Male	3	9.1	nc	(nc-nc)	Female	563	571.6	98.5	(90.5-107.0)
Female	2	3.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	77	83.2	92.6	(73.1-115.7)					
Female	82	83.3	98.4	(78.3-122.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brewster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	20.1	79.4	(45.4-129.0)	Male	15	10.0	149.7	(83.7-247.0)
Female	12	7.1	169.8	(87.7-296.7)	Female	12	7.4	162.9	(84.1-284.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.8	176.8	(57.0-412.6)	Male	1	3.0	nc	(nc-nc)
Female	6	2.3	258.3	(94.3-562.3)	Female	3	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.5	nc	(nc-nc)	Male	9	9.2	97.5	(44.5-185.1)
Female	73	58.2	125.4	(98.3-157.7)	Female	11	8.5	129.4	(64.5-231.5)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	2.1	nc	(nc-nc)	Male	9	5.9	153.0	(69.8-290.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	28	28.1	99.5	(66.1-143.9)	Female	5	6.4	78.0	(25.1-182.0)
Female	23	27.3	84.3	(53.4-126.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	5.6	124.0	(49.7-255.5)
Male	5	4.6	108.4	(34.9-252.9)	Female	6	6.0	99.9	(36.5-217.5)
Female	0	1.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	97	66.9	145.0	(117.6-176.8)
Male	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.7	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	2	3.0	nc	(nc-nc)
Male	5	7.5	66.3	(21.4-154.8)	<u>Testis</u>				
Female	2	4.8	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.8	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	4	5.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	5.7	122.2	(49.0-251.9)	Female	13	12.4	105.1	(55.9-179.8)
Female	6	4.5	134.2	(49.0-292.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	278	240.0	115.8	(102.6-130.3)
Male	2	3.6	nc	(nc-nc)	Female	235	214.9	109.4	(95.8-124.3)
Female	1	1.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	41	36.1	113.6	(81.5-154.1)					
Female	30	32.1	93.5	(63.1-133.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	19.5	92.5	(54.8-146.2)	Male	17	14.1	120.7	(70.3-193.3)
Female	7	6.8	102.8	(41.2-211.8)	Female	19	10.6	178.8	(107.6-279.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.8	nc	(nc-nc)	Male	0	3.2	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	14	12.1	116.0	(63.4-194.7)
Female	85	74.0	114.8	(91.7-142.0)	Female	11	9.3	118.5	(59.1-212.0)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	6	3.6	168.1	(61.4-365.9)	Male	7	8.9	78.3	(31.4-161.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	33	30.4	108.6	(74.8-152.6)	Female	14	7.9	176.3	(96.3-295.8)
Female	28	25.8	108.6	(72.2-157.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	6.0	150.7	(68.8-286.1)
Male	6	5.4	110.4	(40.3-240.3)	Female	2	5.6	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	67	80.8	82.9	(64.2-105.3)
Male	1	2.6	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.8	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	2.7	nc	(nc-nc)
Male	11	10.2	107.5	(53.6-192.4)	<u>Testis</u>				
Female	6	5.5	109.2	(39.9-237.6)	Male	6	5.1	117.8	(43.0-256.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	3.4	145.2	(46.8-338.8)	Male	7	4.0	177.0	(70.9-364.6)
Female	1	0.9	nc	(nc-nc)	Female	15	10.3	145.6	(81.4-240.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	7.3	109.7	(47.3-216.3)	Female	19	15.7	120.9	(72.7-188.8)
Female	4	5.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	286	286.7	99.7	(88.5-112.0)
Male	4	4.9	nc	(nc-nc)	Female	271	249.1	108.8	(96.2-122.6)
Female	0	1.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	32	37.9	84.5	(57.8-119.3)					
Female	35	33.3	105.2	(73.3-146.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brimfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	3.7	164.2	(60.0-357.5)	Male	1	2.3	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.8	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	12	13.1	91.5	(47.2-159.8)	Female	1	1.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	5.6	90.0	(29.0-210.0)	Female	0	1.4	nc	(nc-nc)
Female	5	4.5	111.3	(35.9-259.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.1	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	9	14.8	60.8	(27.7-115.4)
Male	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	0.5	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.9	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.2	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	48	51.0	94.1	(69.4-124.8)
Male	0	0.9	nc	(nc-nc)	Female	42	43.0	97.6	(70.3-131.9)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	9	7.0	128.8	(58.8-244.6)					
Female	6	5.7	105.5	(38.5-229.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brockton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	84	84.7	99.1	(79.1-122.7)	Male	35	53.4	65.6	(45.7-91.2)
Female	27	33.4	80.7	(53.2-117.4)	Female	41	48.1	85.3	(61.2-115.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	17	18.1	93.9	(54.7-150.4)	Male	19	13.5	140.9	(84.8-220.0)
Female	16	15.5	103.1	(58.9-167.4)	Female	8	10.2	78.7	(33.9-155.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.5	nc	(nc-nc)	Male	44	47.1	93.5	(67.9-125.5)
Female	295	339.8	86.8	(77.2-97.3)	Female	43	44.4	96.8	(70.0-130.3)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	34	15.8	214.9	(148.8-300.4)	Male	35	33.4	104.7	(72.9-145.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	136	126.5	107.5	(90.2-127.1)	Female	43	36.6	117.4	(84.9-158.1)
Female	152	127.9	118.8	(100.7-139.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	26	25.2	103.1	(67.3-151.0)
Male	38	22.1	171.7	(121.5-235.7)	Female	32	27.8	115.3	(78.9-162.8)
Female	7	6.5	107.5	(43.1-221.5)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	269	332.1	81.0	(71.6-91.3)
Male	5	8.6	58.3	(18.8-136.0)	<u>Stomach</u>				
Female	3	7.1	nc	(nc-nc)	Male	29	21.0	138.4	(92.6-198.7)
<u>Kidney and Renal Pelvis</u>					Female	16	13.5	118.2	(67.5-192.0)
Male	41	39.8	103.1	(74.0-139.9)	<u>Testis</u>				
Female	26	26.0	100.1	(65.4-146.7)	Male	15	14.9	100.6	(56.3-166.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	16	13.9	115.3	(65.9-187.3)	Male	14	13.2	106.1	(58.0-178.0)
Female	5	4.0	124.3	(40.0-290.0)	Female	56	44.3	126.5	(95.5-164.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	30	29.7	101.0	(68.1-144.2)	Female	65	72.6	89.5	(69.1-114.1)
Female	17	24.6	69.2	(40.3-110.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1164	1164.4	100.0	(94.3-105.9)
Male	21	19.0	110.6	(68.4-169.1)	Female	1196	1171.7	102.1	(96.4-108.0)
Female	5	6.9	72.4	(23.3-169.0)					
<u>Lung and Bronchus</u>									
Male	187	160.8	116.3	(100.2-134.2)					
Female	186	159.6	116.6	(100.4-134.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.5	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	15	12.7	118.3	(66.2-195.2)	Female	1	1.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	0.5	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	5.3	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
Female	7	4.6	153.1	(61.3-315.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	0	0.3	nc	(nc-nc)	Male	10	13.6	73.4	(35.1-135.0)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Kidney and Renal Pelvis</u>					<u>Thyroid</u>				
Male	5	1.6	307.1	(99.0-716.7)	Male	1	0.5	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.6	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Female</u>				
Male	0	1.2	nc	(nc-nc)	Male	38	47.5	79.9	(56.6-109.7)
Female	2	0.8	nc	(nc-nc)	Female	53	42.8	123.9	(92.8-162.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Male</u>				
Male	1	0.8	nc	(nc-nc)	<u>Female</u>				
Female	0	0.2	nc	(nc-nc)	<u>Male</u>				
<u>Lung and Bronchus</u>					<u>Female</u>				
Male	7	6.7	104.2	(41.8-214.8)	<u>Male</u>				
Female	16	6.1	263.8	(150.7-428.4)	<u>Female</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookline

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	44	52.9	83.1	(60.4-111.6)	Male	51	32.8	155.3	(115.6-204.2)
Female	22	22.3	98.6	(61.8-149.3)	Female	52	32.1	162.1	(121.0-212.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	10.4	106.2	(52.9-190.0)	Male	5	8.4	59.7	(19.2-139.3)
Female	10	9.6	103.9	(49.7-191.0)	Female	4	6.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.5	nc	(nc-nc)	Male	42	28.9	145.5	(104.9-196.7)
Female	248	219.3	113.1	(99.4-128.1)	Female	38	29.5	128.9	(91.2-176.9)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	7	10.4	67.2	(26.9-138.5)	Male	14	20.3	69.1	(37.7-115.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	58	78.6	73.8	(56.0-95.4)	Female	30	23.9	125.6	(84.7-179.3)
Female	73	87.5	83.4	(65.4-104.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	16	15.6	102.3	(58.4-166.1)
Male	7	13.6	51.5	(20.6-106.2)	Female	16	18.8	85.1	(48.6-138.2)
Female	4	4.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	214	201.9	106.0	(92.3-121.2)
Male	6	5.2	114.9	(42.0-250.1)	<u>Stomach</u>				
Female	7	4.9	143.6	(57.5-295.9)	Male	9	13.1	68.7	(31.3-130.4)
<u>Kidney and Renal Pelvis</u>					Female	9	9.5	95.2	(43.4-180.7)
Male	26	24.0	108.3	(70.7-158.7)	<u>Testis</u>				
Female	18	16.8	107.3	(63.6-169.6)	Male	15	9.6	155.5	(86.9-256.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	8.5	59.0	(19.0-137.7)	Male	18	8.0	225.4	(133.5-356.2)
Female	1	2.6	nc	(nc-nc)	Female	47	29.3	160.3	(117.8-213.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	25	17.7	141.6	(91.6-209.0)	Female	56	46.4	120.6	(91.1-156.6)
Female	18	15.8	113.6	(67.3-179.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	689	714.0	96.5	(89.4-104.0)
Male	10	11.6	86.6	(41.4-159.2)	Female	815	769.4	105.9	(98.8-113.5)
Female	4	4.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	66	98.7	66.9	(51.7-85.1)					
Female	80	103.0	77.7	(61.6-96.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Buckland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.4	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	7	8.2	85.0	(34.0-175.0)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	3.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.7	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	5	9.2	54.2	(17.5-126.6)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.8	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	25	31.7	78.8	(51.0-116.4)
Male	0	0.5	nc	(nc-nc)	Female	24	27.4	87.6	(56.1-130.3)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	4.4	nc	(nc-nc)					
Female	5	3.7	134.9	(43.5-314.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	25.2	91.1	(57.8-136.8)	Male	19	15.7	121.3	(73.0-189.4)
Female	6	9.1	66.3	(24.2-144.3)	Female	9	12.6	71.5	(32.6-135.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	5.0	159.6	(68.7-314.6)	Male	3	4.1	nc	(nc-nc)
Female	3	4.0	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	15	13.6	110.3	(61.7-181.9)
Female	90	94.9	94.9	(76.3-116.6)	Female	11	11.8	93.6	(46.7-167.5)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	5	4.1	121.4	(39.1-283.3)	Male	5	10.2	49.2	(15.9-114.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	27	37.8	71.4	(47.0-103.9)	Female	3	10.1	nc	(nc-nc)
Female	39	33.0	118.0	(83.9-161.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	7.6	nc	(nc-nc)
Male	8	6.8	117.7	(50.7-231.8)	Female	9	7.3	123.0	(56.1-233.6)
Female	3	1.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	113	108.0	104.7	(86.2-125.8)
Male	2	2.1	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.5	nc	(nc-nc)	Male	4	6.1	nc	(nc-nc)
<u>Kidney and Renal Pelvis</u>					Female	1	3.3	nc	(nc-nc)
Male	7	12.2	57.4	(23.0-118.3)	<u>Testis</u>				
Female	7	7.2	97.4	(39.0-200.6)	Male	6	3.6	165.1	(60.3-359.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	4.4	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	13	11.3	115.1	(61.2-196.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	8.3	157.0	(83.5-268.5)	Female	23	21.2	108.6	(68.8-163.0)
Female	8	6.1	130.8	(56.3-257.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	347	354.9	97.8	(87.8-108.6)
Male	6	5.8	103.6	(37.8-225.4)	Female	323	317.9	101.6	(90.8-113.3)
Female	1	1.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	53	49.8	106.4	(79.7-139.1)					
Female	50	45.3	110.3	(81.9-145.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cambridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	53	73.7	71.9	(53.9-94.1)	Male	47	49.7	94.5	(69.4-125.7)
Female	27	30.0	90.0	(59.3-130.9)	Female	41	48.2	85.0	(61.0-115.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	16.6	78.2	(41.6-133.8)	Male	8	11.8	67.7	(29.1-133.4)
Female	7	14.4	48.7	(19.5-100.3)	Female	9	9.2	98.3	(44.9-186.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	2.1	nc	(nc-nc)	Male	39	43.3	90.0	(64.0-123.0)
Female	296	312.6	94.7	(84.2-106.1)	Female	36	41.2	87.4	(61.2-121.1)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	9	16.1	55.9	(25.5-106.0)	Male	29	29.6	98.1	(65.7-140.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	102	111.0	91.9	(74.9-111.6)	Female	36	34.1	105.6	(74.0-146.2)
Female	90	115.2	78.1	(62.8-96.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	18	21.9	82.2	(48.7-130.0)
Male	10	19.2	52.0	(24.9-95.6)	Female	23	24.8	92.6	(58.7-138.9)
Female	7	5.8	120.1	(48.1-247.5)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	274	285.0	96.1	(85.1-108.2)
Male	11	10.7	102.8	(51.3-184.0)	<u>Stomach</u>				
Female	3	8.8	nc	(nc-nc)	Male	20	18.5	108.0	(65.9-166.8)
<u>Kidney and Renal Pelvis</u>					Female	19	12.2	155.6	(93.7-243.0)
Male	22	34.9	63.0	(39.5-95.4)	<u>Testis</u>				
Female	20	23.6	84.8	(51.7-130.9)	Male	18	21.1	85.4	(50.6-135.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	10	12.0	83.4	(39.9-153.4)	Male	18	13.6	132.5	(78.5-209.4)
Female	3	3.6	nc	(nc-nc)	Female	45	47.1	95.5	(69.6-127.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	17	26.9	63.2	(36.8-101.2)	Female	75	66.5	112.8	(88.8-141.5)
Female	19	22.0	86.2	(51.9-134.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	894	1034.7	86.4	(80.8-92.3)
Male	21	16.7	125.9	(77.9-192.5)	Female	971	1083.1	89.6	(84.1-95.5)
Female	12	6.3	191.0	(98.6-333.7)					
<u>Lung and Bronchus</u>									
Male	106	139.3	76.1	(62.3-92.0)					
Female	106	143.4	73.9	(60.5-89.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Canton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	26.4	91.1	(58.3-135.5)	Male	13	15.2	85.5	(45.5-146.3)
Female	17	10.7	159.5	(92.9-255.4)	Female	8	12.8	62.3	(26.8-122.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.7	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
Female	2	4.1	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	10	13.5	73.8	(35.3-135.8)
Female	86	96.6	89.0	(71.2-109.9)	Female	14	13.4	104.2	(56.9-174.8)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	4.0	nc	(nc-nc)	Male	5	9.5	52.6	(17.0-122.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	42	38.5	109.1	(78.6-147.5)	Female	3	10.5	nc	(nc-nc)
Female	49	41.6	117.9	(87.2-155.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	7.7	129.7	(62.1-238.6)
Male	8	6.6	121.1	(52.1-238.6)	Female	9	9.0	99.8	(45.5-189.4)
Female	1	2.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	102	98.4	103.6	(84.5-125.8)
Male	3	1.9	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.5	nc	(nc-nc)	Male	7	6.4	108.5	(43.5-223.6)
<u>Kidney and Renal Pelvis</u>					Female	3	4.5	nc	(nc-nc)
Male	14	11.5	122.1	(66.7-204.9)	<u>Testis</u>				
Female	7	7.7	91.0	(36.5-187.6)	Male	2	3.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	4.1	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	17	10.6	161.0	(93.7-257.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	8.3	83.9	(33.6-172.9)	Female	19	20.5	92.8	(55.8-144.9)
Female	8	7.2	110.9	(47.7-218.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	331	343.8	96.3	(86.2-107.2)
Male	5	5.5	90.8	(29.3-211.8)	Female	336	345.3	97.3	(87.2-108.3)
Female	4	2.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	41	48.9	83.9	(60.2-113.8)					
Female	46	48.8	94.2	(69.0-125.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;